

CLINUVEL

ASX ANNOUNCEMENT

Melbourne, Australia, 04 March 2025

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

CLINUVEL UNVEILS VITILIGO PROGRAM FOR AMERICAN ACADEMY OF DERMATOLOGY 2025


Pavilion of Photomedicine to engage North American dermatology community

CLINUVEL today unveiled its extensive plans for this year's American Academy of Dermatology (AAD) Annual Meeting in Orlando. Across exhibitions, academic presentations, media and partnerships, CLINUVEL's vitiligo program will feature prominently in and around the AAD from 6–11 March 2025.

"The AAD Meeting is the culmination of more than a year of planning and intensive work to expand the reach and depth of our work in vitiligo," CLINUVEL's Head of North American Operations, Dr Linda Teng said. "We exhibit the world's first Pavilion of Photomedicine, a momentous undertaking by the team to introduce melanocortins and systemic repigmentation to thousands of new medical professionals."

The 4,800 square foot Pavilion of Photomedicine has been custom built for CLINUVEL for the AAD Meeting. The fully enclosed Pavilion provides an immersive experience on the history, evolution, and future of photomedicine, including CLINUVEL's development program with the novel drug SCENESSE® (afamelanotide) to treat vitiligo.

"Thousands of hours of preparation, planning and execution have been invested into a new experience presented as the Pavilion of Photomedicine," CLINUVEL's European General Manager, Mr Lilian Bougy said. "We have sought to combine our innovative technology of melanocortins and a special environment representing our brand, telling our story from A to Z. For an industry used to exhibition booths, we innovate with this presentation, offering information on scientific advancement."



An artist's impressions of CLINUVEL's Pavilion of Photomedicine for the AAD Meeting

Satellite expert meetings

CLINUVEL is supporting three key satellite meetings in the lead up to the AAD Meeting where its results and program are expected to be discussed.

Held on **6 March, the Photodermatology Society Annual Meeting, the Global Vitiligo Foundation (GVF) Annual Symposium**, and **the Skin of Color Society (SOCS) Scientific Symposium** focus intensively on research and developments relevant to CLINUVEL's work and see physicians involved in its commercial and clinical programs presenting and discussing scientific advancements.

"Satellite meetings provide a more intimate, collegiate environment for engaging in depth on clinical topics, new trends and technology of the moment. These meetings facilitate discussion and debate which is not

replicated by the short sessions presented at the main AAD. We are proud to be able to sponsor these three important events and make an active contribution to discussions, a concept that started years ago.” Dr Teng said.

AAD Annual Meeting

The AAD represents a network of over 20,000 dermatology professionals. Its annual meeting is the largest dermatology meeting in North America, attracting dermatologists, researchers, and industry professionals from all over the world.

“In order to succeed in our mission to treat more patients, we must now engage expert clinicians on a grander scale. With the Pavilion of Photomedicine, we differentiate CLINUVEL, provoking the global dermatological community with an intellectual and artistic experience, while respecting the scientific opportunities emerging from our research, development and innovation,” Dr Teng said.

– END –

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACËLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACËLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran’s Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2024 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: mail@clinuvel.com

Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

